Healthcare

OPSUMIT, and the combination OPSYNVI, are treatments for pulmonary arterial hypertension. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.

• Controlling stakeJohnson & Johnson

An oral-care brand in Procter & Gamble's Health Care segment, covering toothbrushes and related products.

• Controlling stakeProcter & Gamble

A personal-health brand in Procter & Gamble's Health Care segment. The 10-K groups it with digestive wellness.

• Controlling stakeProcter & Gamble

PREZISTA is an antiretroviral medicine for HIV. PREZCOBIX and REZOLSTA are darunavir and cobicistat combinations. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.

• Controlling stakeJohnson & Johnson

REMICADE is a treatment for immune-mediated inflammatory diseases. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

RYBREVANT is a treatment for certain non-small cell lung cancers, also sold as RYBREVANT FASPRO. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

Shields Health Solutions provides specialty pharmacy services.

• Portfolio investmentSycamore Partners

Shockwave makes circulatory restoration products for calcified coronary and peripheral artery disease. Johnson & Johnson's fiscal 2025 Form 10-K places it in the MedTech cardiovascular portfolio.

• Controlling stakeJohnson & Johnson

SIMPONI is a treatment for rheumatoid arthritis and other inflammatory diseases, also sold as SIMPONI ARIA. Johnson & Johnson's fiscal 2025 Form 10-K lists both as key Innovative Medicine products.

• Controlling stakeJohnson & Johnson

SPRAVATO is an esketamine nasal spray used with an oral antidepressant for treatment-resistant depression. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

STELARA is a treatment for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key product and says biosimilar competition was reducing sales.

• Controlling stakeJohnson & Johnson

SYMTUZA is a once-daily single-tablet regimen for HIV. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

TALVEY is a bispecific antibody for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

TECNIS is a brand of intraocular lenses for cataract surgery. Johnson & Johnson's fiscal 2025 Form 10-K lists TECNIS in the MedTech Vision portfolio.

• Controlling stakeJohnson & Johnson

TECVAYLI is a bispecific antibody for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

TREMFYA is a treatment for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

UPTRAVI is an oral and intravenous treatment for pulmonary arterial hypertension. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

A personal-health brand in Procter & Gamble's Health Care segment. The 10-K groups it with respiratory treatments.

• Controlling stakeProcter & Gamble

VillageMD includes Village Medical, Summit Health, and CityMD. The acquisition release describes a contingent right tied to a future sale of these interests.

• Portfolio investmentSycamore Partners

XARELTO is an oral anticoagulant. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and says it was co-developed with Bayer HealthCare AG.

• Controlling stakeJohnson & Johnson